Bromide

Bromide

SCHEMBL164301

CCCCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1.[Br-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.56
TRAP1 Q12931 2/20 0.46
CHRNA7 P36544 7/20 0.45
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
DNM1 Q05193 2/20 0.43
CSNK1E P49674 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL286882 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL2446607 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL678415 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL362235 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL1866839 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL7759526 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL635580 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL8775234 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL2979400 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL1963378 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118209650-A Method for extracting and determining succinate dehydrogenase inhibitor based on magnetic eutectic solvent-liquid microextraction-high performance liquid chromatography 山西农业大学 2024-06-18 CN claimed
CN-111944005-B Cholic acid-hexyl-triphenyl phosphonium bromide and preparation method and application thereof 首都医科大学 2023-04-18 CN claimed
CN-115417769-A Method for synthesizing sex pheromone component of tomato leaf miner and intermediate 昆明博鸿科技有限公司 2022-12-02 CN claimed
CN-115337297-A CPI-613 mitochondrion targeted small molecule prodrug, self-assembled nanoparticles thereof, preparation method and application 沈阳药科大学 2022-11-15 CN claimed
CN-114318853-A Modified antibacterial fiber 安徽润齐新材料科技有限公司 2022-04-12 CN claimed
CN-113278086-A Antibacterial material of quaternary phosphonium salt modified locust bean gum 广州市尚信净化工程有限公司 2021-08-20 CN claimed
EP-2069452-B1 ONIUM-CONTAINING CMP COMPOSITIONS AND METHODS OF USE THEREOF CABOT MICROELECTRONICS CORP (US) 2016-11-09 EP claimed
US-20160297829-A1 METHOD FOR PRODUCING AVENACIOLIDES AND USES THEREOF ACADEMIA SINICA (TW) 2016-10-13 US claimed
US-9129907-B2 Onium-containing CMP compositions and methods of use thereof CABOT MICROELECTRONICS CORPORATION (US) 2015-09-08 US claimed
EP-1973974-B1 A PROCESS FOR PREPARING 'ONIUM SALTS SUN CHEMICAL CORP (US) 2014-04-30 EP claimed
US-6086661-A (A)IMIDAZOLINIUM QUATERNARY SALT, (B) PHOSPHONIUM QUATERNARY SALT, OR (C) AN AMMONIUM QUATERNARY SALT; A PAPER-CURL REDUCING COMPOUND; DYE; STABILIZERS, BIOCIDE, WATER SOLUBLE SALT XEROX CORPORATION (US) 2000-07-11 US claimed
US-5760809-A INK JET PRINTING XEROX CORPORATION (US) 1998-06-02 US claimed
US-5709976-A Coated papers XEROX CORPORATION (US) 1998-01-20 US claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0615853-B1 Recording sheets containing phosphonium compounds XEROX CORP (US) 1996-10-16 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
EP-0615853-A1 Recording sheets containing phosphonium compounds XEROX CORPORATION (US) 1994-09-21 EP claimed
US-4532274-A Also containing polyol, hardener, catalyst, aluminum trihydrate UNION CARBIDE CORPORATION (US) 1985-07-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297829-A1 METHOD FOR PRODUCING AVENACIOLIDES AND USES THEREOF COASY, ERG28, GSK3B HIF1A 4070/4885TRAP1 2409/4885CHRNA7 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.